{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:34:43Z","timestamp":1791380083278,"version":"4.3.3"},"reference-count":21,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nBuprenorphine, a partial opioid agonist, has gained attention for its use in chronic pain management due to its lower risk of abuse and respiratory depression compared to traditional opioids. The utilization of buprenorphine for chronic pain has increased in recent years. This study aimed to analyze trends in buprenorphine prescribing for chronic pain in an outpatient setting over an 18-month period, excluding buprenorphine-naloxone combinations used for opioid use disorder and opioid dependence.\nMethods\nA retrospective chart review was conducted, examining outpatient buprenorphine and long-acting opioid prescriptions issued by three pain management physicians between January 1, 2023, and June 30, 2024. Prescription data were collected from electronic medical records (EMRs) and analyzed across three six-month intervals: January 1, 2023, to June 30, 2023; July 1, 2023, to December 31, 2023; and January 1, 2024, to June 30, 2024. Only unique buprenorphine prescriptions for chronic pain management were included, while buprenorphine-naloxone prescriptions for opioid use disorder were excluded. Long-acting opioids analyzed included extended release (ER) formulations including tramadol ER, morphine ER, hydrocodone ER, oxycodone ER, fentanyl, and methadone.\nResults\nOver the 18-month study period, a total of 61 unique buprenorphine prescriptions for chronic pain were issued by the three physicians. The number of prescriptions increased across each six-month period: 18 prescriptions were issued between January 1, 2023, and June 30, 2023; 20 prescriptions from July 1, 2023, to December 31, 2023; and 23 prescriptions from January 1, 2024, to June 30, 2024. This represents a 27.8% increase over the entire 18-month period. During the same timeframe, 117 long-acting opioid prescriptions (excluding buprenorphine) were issued in the first six-month period, 121 prescriptions in the second period, and 108 prescriptions in the third period. Buprenorphine prescriptions accounted for 13.3% of all long-acting opioid prescriptions in the first period (18 out of 135 total prescriptions), 14.2% in the second period (20 out of 141 total prescriptions), and 17.6% in the third period (23 out of 131 total prescriptions). Notably, while the absolute number of buprenorphine prescriptions increased steadily, its proportion relative to total long-acting opioid prescriptions also grew over time.\nConclusions\nThe findings demonstrate a steady increase in buprenorphine prescribing for chronic pain in the outpatient setting, while long-acting opioid prescriptions exhibited a slight decline in the later periods. The proportion of buprenorphine prescriptions relative to long-acting opioids increased over time, suggesting growing acceptance of buprenorphine as a safer alternative for chronic pain management. Further research is needed to explore the factors driving these prescribing patterns and the long-term clinical outcomes associated with buprenorphine use in chronic pain management.<\/jats:p>","DOI":"10.64719\/pb.4529","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"8-19","source":"Crossref","is-referenced-by-count":8,"title":["Trends in Outpatient Buprenorphine Prescribing for Chronic Pain: A Retrospective Analysis Over 18 Months"],"prefix":"10.64719","volume":"55","author":[{"given":"Jamal","family":"Hasoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahish","family":"Chitneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnad","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Rikard SM, Strahan AE, Schmit KM, Guy GP., Jr Chronic Pain Among Adults \u2013 United States, 2019\u20132021. MMWR Morb Mortal Wkly Rep. 2023;72(15):379\u2013385. doi: 10.15585\/mmwr.mm7215a1. Published 2023 Apr 14.","DOI":"10.15585\/mmwr.mm7215a1"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Latina R, De Marinis MG, Giordano F et al. Epidemiology of Chronic Pain in the Latium Region, Italy: A Cross-Sectional Study on the Clinical Characteristics of Patients Attending Pain Clinics. Pain Manag Nurs. 2019;20(4):373\u2013381. doi: 10.1016\/j.pmn.2019.01.005.","DOI":"10.1016\/j.pmn.2019.01.005"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405\u2013416. doi: 10.1037\/a0013628.","DOI":"10.1037\/a0013628"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Kaye AM, Knezevic NN et al. Comprehensive, Evidence-Based, Consensus Guidelines for Prescription of Opioids for Chronic Non-Cancer Pain from the American Society of Interventional Pain Physicians (ASIPP) Pain Physician. 2023;26(7S):S7\u2013S126.","DOI":"10.36076\/ppj.2023.26.S7"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Kumar VM, Agboola F, Synnott PG et al. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model. Value Health. 2019;22(4):416\u2013422. doi: 10.1016\/j.jval.2018.12.005.","DOI":"10.1016\/j.jval.2018.12.005"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Webster L, Gudin J, Raffa RB et al. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Med. 2020;21(4):714\u2013723. doi: 10.1093\/pm\/pnz356.","DOI":"10.1093\/pm\/pnz356"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Case AA, Kullgren J, Anwar S, Pedraza S, Davis MP. Treating Chronic Pain with Buprenorphine-The Practical Guide. Curr Treat Options Oncol. 2021;22(12):116. doi: 10.1007\/s11864-021-00910-8. Published 2021 Nov 18.","DOI":"10.1007\/s11864-021-00910-8"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Spinella S, McCarthy R. Buprenorphine for Pain: A Narrative Review and Practical Applications. Am J Med. 2024;137(5):406\u2013413. doi: 10.1016\/j.amjmed.2024.01.022.","DOI":"10.1016\/j.amjmed.2024.01.022"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hasoon J, Nguyen A, Urits I, Robinson C, Viswanath O, Kaye AD. A Need for Further Education on Buprenorphine in Pain Medicine. Health Psychol Res.. 2023;11:74958. doi: 10.52965\/001c.74958. Published 2023 May 24.","DOI":"10.52965\/001c.74958"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dalal S, Chitneni A, Berger AA et al. Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychol Res. 2021;9(1):27241. doi: 10.52965\/001c.27241. Published 2021 Aug 6.","DOI":"10.52965\/001c.27241"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Poliwoda S, Noor N, Jenkins JS et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3):37517. doi: 10.52965\/001c.37517. Published 2022 Aug 20.","DOI":"10.52965\/001c.37517"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Vu PD, Bansal V, Chitneni A et al. Buprenorphine for Chronic Pain Management: a Narrative Review. Curr Pain Headache Rep. 2023;27(12):811\u2013820. doi: 10.1007\/s11916-023-01185-4.","DOI":"10.1007\/s11916-023-01185-4"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Karp JF, Butters MA, Begley AE et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(08):e785\u2013e793.","DOI":"10.4088\/JCP.13m08725"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Khanna I, Pillarisetti S. Buprenorphine \u2013 an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. doi: 10.2147\/JPR.S85951. Published online December 2015:859.","DOI":"10.2147\/JPR.S85951"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Chin Beng Lim S, Schug S, Krishnarajah J. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. Pain Med. 2019;20(1):143\u2013152. doi: 10.1093\/pm\/pnx321.","DOI":"10.1093\/pm\/pnx321"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Gudin J, Fudin J. A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. Pain Ther. 2020;9(1):41\u201354. doi: 10.1007\/s40122-019-00143-6.","DOI":"10.1007\/s40122-019-00143-6"},{"key":"ref17","unstructured":"Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician. 2006;73(9):1573\u20131578."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40:17\u201325.","DOI":"10.1016\/0376-8716(95)01186-2"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002207.","DOI":"10.1002\/14651858.CD002207.pub2"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Huang TL, Huang YM, Hou MM, Lu CH, Chao TY, Chiu TJ, Chang YS, Lin SH, Lin CH, Chen YH, Wang CH, Chen JS, Shen WC. Safety and effectiveness of transdermal buprenorphine in cancer pain: An observational study in Taiwan (SOOTHE) Asia Pac J Clin Oncol. 2023;19(2):e45\u2013e53. doi: 10.1111\/ajco.13772. Epub 2022 May 22.","DOI":"10.1111\/ajco.13772"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Silveira M, Powell V. Buprenorphine for Cancer Pain: Results from a Systematic Review. J Opioid Manag. 2024;20(4):B12. doi: 10.5055\/bupe.24.rpj.1075.","DOI":"10.5055\/bupe.24.rpj.1075"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:28Z","timestamp":1791315208000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/trends-in-outpatient-buprenorphine-prescribing-for-chronic-pain-a-retrospective-analysis-over-18-months\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4529","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}